Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 188

1.

S32212, a novel serotonin type 2C receptor inverse agonist/α2-adrenoceptor antagonist and potential antidepressant: II. A behavioral, neurochemical, and electrophysiological characterization.

Dekeyne A, Brocco M, Loiseau F, Gobert A, Rivet JM, Di Cara B, Cremers TI, Flik G, Fone KC, Watson DJ, Papp M, Sharp T, Serres F, Cespuglio R, Olivier B, Chan JS, Lavielle G, Millan MJ.

J Pharmacol Exp Ther. 2012 Mar;340(3):765-80. doi: 10.1124/jpet.111.187534. Epub 2011 Dec 16.

PMID:
22178753
2.

S32212, a novel serotonin type 2C receptor inverse agonist/α2-adrenoceptor antagonist and potential antidepressant: I. A mechanistic characterization.

Millan MJ, Mannoury la Cour C, Chanrion B, Dupuis DS, Di Cara B, Audinot V, Cussac D, Newman-Tancredi A, Kamal M, Boutin JA, Jockers R, Marin P, Bockaert J, Muller O, Dekeyne A, Lavielle G.

J Pharmacol Exp Ther. 2012 Mar;340(3):750-64. doi: 10.1124/jpet.111.187468. Epub 2011 Dec 16.

PMID:
22178752
3.

S32006, a novel 5-HT2C receptor antagonist displaying broad-based antidepressant and anxiolytic properties in rodent models.

Dekeyne A, Mannoury la Cour C, Gobert A, Brocco M, Lejeune F, Serres F, Sharp T, Daszuta A, Soumier A, Papp M, Rivet JM, Flik G, Cremers TI, Muller O, Lavielle G, Millan MJ.

Psychopharmacology (Berl). 2008 Sep;199(4):549-68. doi: 10.1007/s00213-008-1177-9. Epub 2008 Jun 4.

PMID:
18523738
4.

S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: III. Actions in models of potential antidepressive and anxiolytic activity in comparison with ropinirole.

Millan MJ, Brocco M, Papp M, Serres F, La Rochelle CD, Sharp T, Peglion JL, Dekeyne A.

J Pharmacol Exp Ther. 2004 Jun;309(3):936-50. Epub 2004 Feb 20.

PMID:
14978196
6.

S41744, a dual neurokinin (NK)1 receptor antagonist and serotonin (5-HT) reuptake inhibitor with potential antidepressant properties: a comparison to aprepitant (MK869) and paroxetine.

Millan MJ, Dekeyne A, Gobert A, Mannoury la Cour C, Brocco M, Rivet JM, Di Cara B, Lejeune F, Cremers TI, Flik G, de Jong TR, Olivier B, de Nanteuil G.

Eur Neuropsychopharmacol. 2010 Sep;20(9):599-621. doi: 10.1016/j.euroneuro.2010.04.003. Epub 2010 May 18.

PMID:
20483567
7.

Antidepressant-like properties of the anti-Parkinson agent, piribedil, in rodents: mediation by dopamine D2 receptors.

Brocco M, Dekeyne A, Papp M, Millan MJ.

Behav Pharmacol. 2006 Nov;17(7):559-72.

PMID:
17021388
9.

The serotonin1A receptor partial agonist S15535 [4-(benzodioxan-5-yl)1-(indan-2-yl)piperazine] enhances cholinergic transmission and cognitive function in rodents: a combined neurochemical and behavioral analysis.

Millan MJ, Gobert A, Roux S, Porsolt R, Meneses A, Carli M, Di Cara B, Jaffard R, Rivet JM, Lestage P, Mocaer E, Peglion JL, Dekeyne A.

J Pharmacol Exp Ther. 2004 Oct;311(1):190-203. Epub 2004 May 14.

PMID:
15146031
10.

Anxiolytic properties of agomelatine, an antidepressant with melatoninergic and serotonergic properties: role of 5-HT2C receptor blockade.

Millan MJ, Brocco M, Gobert A, Dekeyne A.

Psychopharmacology (Berl). 2005 Feb;177(4):448-58. Epub 2004 Jul 31.

PMID:
15289999
11.

On the mechanism of antidepressant-like action of berberine chloride.

Kulkarni SK, Dhir A.

Eur J Pharmacol. 2008 Jul 28;589(1-3):163-72. doi: 10.1016/j.ejphar.2008.05.043. Epub 2008 Jun 3.

PMID:
18585703
13.

Serotonin(2C) receptors tonically suppress the activity of mesocortical dopaminergic and adrenergic, but not serotonergic, pathways: a combined dialysis and electrophysiological analysis in the rat.

Gobert A, Rivet JM, Lejeune F, Newman-Tancredi A, Adhumeau-Auclair A, Nicolas JP, Cistarelli L, Melon C, Millan MJ.

Synapse. 2000 Jun 1;36(3):205-21.

PMID:
10819900
14.

Behavioral and serotonergic consequences of decreasing or increasing hippocampus brain-derived neurotrophic factor protein levels in mice.

Deltheil T, Guiard BP, Cerdan J, David DJ, Tanaka KF, Repérant C, Guilloux JP, Coudoré F, Hen R, Gardier AM.

Neuropharmacology. 2008 Nov;55(6):1006-14. doi: 10.1016/j.neuropharm.2008.08.001. Epub 2008 Aug 12. Review.

PMID:
18761360
16.

S18616, a highly potent spiroimidazoline agonist at alpha(2)-adrenoceptors: II. Influence on monoaminergic transmission, motor function, and anxiety in comparison with dexmedetomidine and clonidine.

Millan MJ, Lejeune F, Gobert A, Brocco M, Auclair A, Bosc C, Rivet JM, Lacoste JM, Cordi A, Dekeyne A.

J Pharmacol Exp Ther. 2000 Dec;295(3):1206-22.

PMID:
11082458
17.

The melanin-concentrating hormone1 receptor antagonists, SNAP-7941 and GW3430, enhance social recognition and dialysate levels of acetylcholine in the frontal cortex of rats.

Millan MJ, Gobert A, Panayi F, Rivet JM, Dekeyne A, Brocco M, Ortuno JC, Di Cara B.

Int J Neuropsychopharmacol. 2008 Dec;11(8):1105-22. doi: 10.1017/S1461145708008894. Epub 2008 May 9.

PMID:
18466669
19.

Behavioral effects of the beta3 adrenoceptor agonist SR58611A: is it the putative prototype of a new class of antidepressant/anxiolytic drugs?

Consoli D, Leggio GM, Mazzola C, Micale V, Drago F.

Eur J Pharmacol. 2007 Nov 14;573(1-3):139-47. Epub 2007 Jul 4.

PMID:
17669397
20.

Mirtazapine enhances frontocortical dopaminergic and corticolimbic adrenergic, but not serotonergic, transmission by blockade of alpha2-adrenergic and serotonin2C receptors: a comparison with citalopram.

Millan MJ, Gobert A, Rivet JM, Adhumeau-Auclair A, Cussac D, Newman-Tancredi A, Dekeyne A, Nicolas JP, Lejeune F.

Eur J Neurosci. 2000 Mar;12(3):1079-95.

PMID:
10762339

Supplemental Content

Support Center